author-photo

Charu Kanwal

Hoffmann-La Roche

8

Papers

148

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
LBA55Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone.

2011 Toxicology Letters
Show All
- Source
- Cite
- Save
Citations (14)
Serum cardiac troponin I concentrations transiently increase in rats given rosiglitazone

2011 Fuel and Energy Abstracts
Show All
- Source
- Cite
- Save
Citations (7)
Primary Endothelial Damage Is the Mechanism of Cardiotoxicity of Tubulin-Binding Drugs

2010 Toxicological Sciences
Show All
- Source
- Cite
- Save
Citations (52)
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients

2009 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (18)